GenomOncology’s Molecular Tumor Board solution enables clinicians to make powerful decisions through a fully integrated workflow from case creation, to alteration introspection, to alteration driven treatment and clinical trial investigation, and to Molecular Tumor Board presentations.
Our solution interprets NGS variants as well as biomarker concepts including protein expressions, chromosomal markers, rearrangements, and more. Users also have access to My Cancer Genome content and annotation databases.
Our variant interpretations are combined with disease and other clinical criteria to suggest potential treatments and clinical trials. Our suggestions are easy to navigate through and are backed by a full evidence model.
Our reporting and exporting capabilities allow users to generate flexible presentations and reports that update automatically. These reports can then be exported and sent directly to your EHR or to any referring provider easily.
Given the complex nature of both cancer as a disease and the field of molecular oncology, our KMS platform is an AI system that understands the language of oncology, particularly cancer genomics, with unsurpassed depth.
GO tools support the parsing and interpretation of NGS variants as well as biomarker concepts. GO HGVS parser can decipher all variant types, including insertions, deletions, substitutions, intronic, splice and promoter data. The biomarker model is not limited to simple genetic alterations: Fusion data, copy number changes, protein expression information acquired via IHC (ER, PR, MSI, PD-L1, etc.) can also trigger rules. The KMS also contains a full cytogenetics engine that parses out the individual aberrations from ISCN strings and uses those concepts, e.g.” i(17)(q10)” implies “del(17)(p10)” in triggering rules content. As a result, GO Clinical Oncology tools are uniquely able to handle, understand and integrate the array of tests and variables required to make decisions for the range of cancer patients – from solid tumors to the complex array of hematologic malignancies.
Relevant therapies for the patient’s tumor type(s) and/or for other tumor type(s) are generated based on patient information. These recommendations can be selected for inclusion on the final Tumor Board report/presentation. These therapy and prognosis recommendations are populated from FDA, NCCN, ASCO and MCG guidelines contained within the GO KMS. Therapies that have a source of FDA indicate that that therapy is recommended on-label by the FDA in the package insert.
Institutions may create their own therapeutic and prognostic assertions (using the Curation UI) and/or may overrule the assertions identified in GO KMS. All assertions are presented to the user and can be selected to be included in the final report. We have the ability to create different filters to allow for variation of the types of off-label recommendations based on institution preferences (e.g, not display MCG content).
Clinical trial recommendations are sourced from clinicaltrials.gov, and cancer.gov trials are curated by the team at My Cancer Genome on a weekly basis.
All relevant trials that match based on the conditions of the case can be presented. At present, there are >2000 fully curated biomarker-driven trials in our system that have been curated by the My Cancer Genome team.
The GO Tumor Board solution was designed to support a fully integrated workflow from case creation to recommendations report sign-off.
“Cases Like Mine” enables the user to similar cases in the Data warehouse.
“Cases Like Mine” enables the user to view key data/statistics of similar cases in the database. This can be limited just to an institution's historical set or the user may elect to share data and access the broader set of data in GO’s cancer center network to improve decision-making through real-world data.
The GO Oncology Data Warehouse integrates clinical and molecular data overlaid with powerful analytic capabilities via GenomAnalytics.